Hutchison China Meditech Limited Additional Listing (2369B)
15 June 2016 - 5:09PM
UK Regulatory
TIDMHCM
RNS Number : 2369B
Hutchison China Meditech Limited
15 June 2016
Block Admission
London: Wednesday, June 15, 2016: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that an
application has been made to the London Stock Exchange plc for a
block admission of 1,000,000 ordinary shares, par value of US$1.00
each ("Ordinary Shares") to be admitted to trading on AIM. It is
expected that such admission will become effective on June 20,
2016.
These Ordinary Shares will be issued from time to time pursuant
to the exercise of share options under the Share Option Scheme
adopted by Chi-Med on May 13, 2016. When issued, these Ordinary
Shares will be credited as fully paid and will rank pari passu with
the existing Ordinary Shares in issue.
NOTES TO EDITORS
About Chi-Med
Chi-Med is a China-based, globally-focused healthcare group
which researches, develops, manufactures and sells pharmaceuticals
and health-related consumer products. Its Innovation Platform,
Hutchison MediPharma Limited, is focused on discovering, developing
and commercializing innovative therapeutics in oncology and
autoimmune diseases. Its pipeline of eight novel oral compounds for
cancer and inflammation is in development in North America, Europe,
Australia and Greater China.
Chi-Med's Commercial Platform manufactures, markets and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
Contacts
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Jillian Connell, The Trout Group +1 (646) 378 2956 jconnell@troutgroup.com
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSGGUWUQUPQUMA
(END) Dow Jones Newswires
June 15, 2016 03:09 ET (07:09 GMT)